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Introduction
Cardiovascular disorder, particularly atherosclerotic cor-
onary artery disease (CAD), is the leading cause of mor-
bidity and mortality in end-stage renal disease (ESRD) 
patients on maintenance hemodialysis [1]. Both preva-
lence and annual mortality for CAD are much higher in 
hemodialyzed patients compared to the age-matched gen-
eral population (40 vs 7.3 % and 9 vs .28 %, respectively) 
[2]. The above data support the hypothesis that pathogen-
esis and manifestation of CAD differ in the presence of 
renal failure. CAD is a multifactorial, polygenic disease 
with environmental and genetic determinants. The accu-
mulation of traditional cardiovascular predictors does 
not fully explain an excess risk of CAD in hemodialyzed 
patients [3]. The evaluation of novel risk factors, pre-
dominantly genetic markers, is thus essential to improve 
CAD risk stratification in patients with ESRD. Over the 
years, the candidate gene approach and genome-wide 
association studies have successfully identified CAD sus-
ceptibility genes in a general population. However, the 
number of such studies in ESRD patients remains limited 
[4, 5].
Renalase is a recently discovered flavin adenine dinucle-
otide (FAD)-dependent amine oxidase, not only expressed 
in kidneys, but also observed in cardiomyocytes, the nerv-
ous system and endothelium [6]. It degrades circulating 
catecholamines and thus regulates blood pressure and car-
diac function [7]. It was suggested that renalase may play 
a key role in the pathogenesis of cardiovascular complica-
tions among patients with ESRD [8].
Renalase gene (RNLS) resides on chromosome 10 
(10q23.31), has 13 exons and encodes a 342 amino acids 
protein with a calculated molecular mass of ~38 kDa. 
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Recent studies have explored the association between vari-
ants in the renalase gene and an increased risk of cardiovas-
cular disorders [9, 10].
The aim of the present study was to investigate the 
association between rs10887800 and rs2576178 renalase 




The case–control study population comprised 309 
patients with end-stage renal disease (ESRD) undergo-
ing hemodialysis, consecutively enrolled between Janu-
ary 2012 and December 2013. Overall, there were 157 
males (50.8 %) and 152 females (49.2 %). Mean age was 
64.1 ± 14.1 years. ESRD resulted from diabetic nephrop-
athy (23 %), chronic glomerulonephritis (18.2 %), hyper-
tensive nephropathy (12.6 %), polycystic kidney disease 
(10 %), interstitial nephritis (9.1 %), obstructive nephropa-
thy (8.4 %) and other or unknown causes (18.7 %). A posi-
tive family history of CAD in first-degree relatives was 
reported by 42 patients (13.6 %).
All recruited patients underwent HD procedure three 
times a week—3 to 5 h each at five dialysis centers in 
eastern Poland. Blood samples for genetic studies were 
taken into EDTA tubes from the venous part of the dialy-
sis access at the beginning of HD. All HD patients under-
went 12-lead resting electrocardiography (ECG). Baseline 
demographic and clinical data (including signs and symp-
toms of CAD) were obtained from a standardized interview 
and a physical examination, both provided by a specialist 
from the Department of Nephrology in Lublin. The clini-
cal data were complemented by the analysis of medical 
records. Patients enrolled in the study were divided into 
two subgroups according to the presence of coronary artery 
disease (CAD): the CAD+ group consisted of 107 patients 
with CAD and the CAD− group consisted of 202 patients 
without CAD.
The CAD diagnosis was based on the criteria of the 
European Society of Cardiology (ESC).
Patients were enrolled to the CAD+ group if they met at 
least one of the following inclusion criteria: (1) history of 
CAD, myocardial infarction or angina pectoris, (2) previ-
ous percutaneous coronary intervention or coronary artery 
bypass surgery, (3) abnormal coronary angiography or CT 
angiography result.
Patients with other cardiac diseases such as hypertrophic 
or dilated cardiomyopathy, aortic stenosis or pericarditis 
were excluded from the study.
Genotype determination
Genomic DNA was isolated from peripheral blood leuko-
cytes according to the technique of Madisen et al. [11] with 
minor modifications.
Genotypes for two SNPs in the renalase gene (dbSNP 
Accession Numbers: rs2576178 and rs10887800) were 
determined by the polymerase chain reaction–restriction 
fragment length polymorphism (PCR–RFLP) method. 
The following primers were used for amplification: for 
rs2576178 polymorphism forward 5′-AGCAGAGAA-
GCAGCTTAACCT-3′ and reverse: 5′-TTATCTGCAA-
GTCAGCGTAAC-3′ and for rs10887800 polymorphism 
forward: 5′-CAGGAAAGAAAAGAGTTGACAT-3′ and 
reverse: 5′-AAGTTGTTCCAGCTACTGT-3′. Genomic 
DNA (300 ng) was amplified in a final volume of 
30 µl, containing: 10 mM TRIS–HCl buffer (pH 8.3), 
50 mM KCl, 1.5 mM MgCl2, 200 µM each dNTP, 1 µM 
of each primer and 2 U Taq polymerase (all reagents from 
MBI Fermentas, St. Leon-Rot, Germany). Amplification 
of DNA was performed in a PTC 200 Thermal Cycler (MJ 
Research, Inc. Waltham, MA) with the initial denatura-
tion at 95 °C for 6 min, followed by 35 cycles at 94 °C for 
30 s, annealing at 60 °C for 30 s and extension at 72 °C for 
1 min. The final extension step was at 72 °C for 7 min. The 
PCR products (10 µl) were digested for 6–10 h with 5 U of 
restriction endonucleases (Pst I for rs10887800 and Msp I 
for rs2576178 polymorphism) at 37 °C. The resulting DNA 
fragments were separated by electrophoresis on 2, 5 % aga-
rose gel. After digestion with Pst I endonuclease, the PCR 
fragment sizes were: 554 bp (undigested) for A allele and 
415 + 139 bp for a polymorphic variant (G allele). After 
digestion with Msp I, the fragment sizes were: 525 bp 
(undigested) for A allele and 423 bp + 102 bp in case of 
a polymorphic variant (G allele; both endonucleases from 
MBI Fermentas, Germany).
Statistical analysis
Statistical analyses were performed using the IBM SPSS 
Statistics for Windows, version 20 (IBM Corp., Armonk, 
NY, USA). Baseline differences between two independent 
groups were evaluated by a Chi-square test of independence 
(for categorical variables) and a Student’s t test for means 
of continuous variables. Hardy–Weinberg equilibrium was 
assessed by a goodness-of-fit Chi-square test. Genotype 
distribution and allele frequencies were compared between 
groups using a 2 × 2 contingency Chi-square test. A mul-
tivariate logistic regression analysis was used to assess the 
genotypes impact on a CAD risk adjusted by age, gender, 
BMI, diabetes mellitus, hypertension, smoking, hyperlipi-
demia and stroke in anamnesis as potential confounders. 
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Adjusted OR with 95 % confidence intervals (CI) was cal-
culated. Each genotype was assessed under 2-df codomi-
nant, 1-df dominant and 1-df recessive genetic models of 
inheritances. The wild-type homozygous group was the ref-
erence group for comparisons. All p values were two-sided 
and p < .05 was considered to indicate statistically signifi-
cant differences.
Results
Two renalase gene polymorphisms: rs10887800 (intron 
6) and rs2576178 (5′ flanking region) were genotyped in 
107 CAD+ patients and 202 CAD− patients. The baseline 
characteristics of the studied groups are summarized in 
Table 1.
The CAD+ patients were older (69.61 ± 10.51 vs 
61.20 ± 14.83, p < .001) and more frequently male (59.8 
vs 46 %, p < .001). As expected, compared to the CAD−, 
the CAD+ patients had a lower hemoglobin and albumin 
level and a higher prevalence of concomitant diseases, 
including diabetes mellitus and hyperlipidemia. Stroke in 
anamnesis was reported more often in the CAD+ group, 
but the difference was not statistically significant. The 
CAD+ patients were also more likely to have a history 
of cardiovascular disorders in a first-degree relative and a 
higher BMI mean value.
Genotype distribution and allele frequencies of 
rs10887800 and rs2576178 renalase gene polymorphisms 
were compared in the groups of patients with and without 
CAD. Genotyping results for these two polymorphisms are 
summarized in Table 1. The genotype distribution in all 
examined groups was in Hardy–Weinberg equilibrium.
For the rs10887800 polymorphism, no significant dif-
ferences in allele frequencies were observed between 
groups. However, the frequency of the G allele in the 
CAD+ group was higher than in CAD− (.54 vs .47) and 
the difference showed a trend toward significance, OR 1.34 
(95 % CI .96–1.86), p = .088. The analysis of the geno-
type distribution showed that there was significant differ-
ence in the frequency of GG genotype between CAD+ 
and CAD− groups [GG vs AG + AA], OR 1.78 (95 % CI 
1.04–3.03), p = .035. The data were further examined by 
the logistic regression analysis for three models of genetic 
inheritance. After adjustment for age, sex, BMI, smok-
ing status, hyperlipidemia, diabetes mellitus, hyperten-
sion and stroke in anamnesis, rs10887800GG genotype 
was associated with the increased risk of CAD under the 
codominant model [GG vs AA; adjusted OR 2.66 (95 % 
CI 1.19–5.94), p = .017] and under the recessive model 
Table 1  Demographic and 
clinical characteristics of 
studied groups
Continuous variables are presented as mean ± SD. Discrete variables are presented as numbers and per-
centages (in parentheses)
EPO erythropoietin, CVD cardiovascular disorder, CAD coronary artery disease
Variables CAD+ (n = 107) CAD− (n = 202) p value
Age (years) 69.61 ± 10.51 61.20 ± 14.83 <.001
Sex (M/F) 64/43 93/109 <.001
Dialysis duration (years) 6.01 ± 6.16 6.52 ± 6.40 >.050
BMI (kg/m2) 27.47 ± 5.62 24.87 ± 4.93 <.001
Albumin (g/dl) 3.86 ± .36 3.98 ± .39 <.050
Hemoglobin (g/dl) 10.6 ± 1.3 11.00 ± 1.45 <.050
EPO demand (IU)/week 3841.58 ± 2704.04 3568.42 ± 2793.81 >.050
Diabetes mellitus (%) 48 (44.9) 41 (20.4) <.050
Stroke in anamnesis (%) 13 (12.1) 12 (6.0) >.050
Hyperlipidemia (%) 65 (61.3) 87 (43.5) <.010
Family history of CVD 21 (19.6) 21 (10.4) <.010
Smoking 21 (19.6) 27 (13.4) >.050
Alcoholism 2 (1.9) 6 (3) >.050
Rs10887800
 GG/AG/AA 32/51/24 39/110/53 .108
 GG versus (AG + AA) 32/75 39/163 .035
 G versus A .54/.46 .47/.53 .088
Rs2576178
 GG/AG/AA 10/43/54 13/75/114 .490
 G versus A .29/.71 .25/.75 .251
874 Int Urol Nephrol (2016) 48:871–876
1 3
[GG vs AG + AA; adjusted OR 2.10 (95 % CI 1.10–4.02), 
p = .025], Table 2.
For the rs2576178 polymorphism, no significant differ-
ences in allele and genotype frequencies were observed 
between groups. By multivariate analysis, the rs2576178 
polymorphism did not influence the risk of CAD, Table 3.
Discussion
In the present case–control study, we found that the 
rs10887800 renalase gene polymorphism significantly 
increased the risk of CAD in hemodialyzed patients. More-
over, the rs10887800 polymorphism affected the CAD 
risk independently of age, sex and other CAD risk factors, 
including smoking, BMI, hyperlipidemia, arterial hyperten-
sion and diabetes mellitus.
By multivariate logistic regression analysis, we found 
that under the codominant model patients with GG geno-
type had almost threefold higher risk of CAD compared to 
AA carriers. Under the recessive model, the risk of CAD 
was approximately twofold higher for G allele homozy-
gotes than for A allele carriers.
As far as the authors know, no other papers concerning 
the association between renalase gene polymorphisms and 
CAD risk in ESRD patients have been published. In our 
previous study of 369 dialyzed patients, we found a link 
between two SNPs in the renalase gene and arterial hyper-
tension. The G allele of both rs10887800 and rs2576178 
polymorphisms was associated with an increased risk of 
hypertension (1.76 and 1.55 times, respectively) [12]. In 
another study of patients with chronic kidney disease from 
North India, the rs2576178 polymorphism did not affect 
the risk of hypertension. However, these authors observed 
that the CC genotype and the C allele of the rs2296545 
renalase gene polymorphism were related to hypertensive 
nephropathy [13].
So far, a few studies have evaluated an association 
between SNPs in the renalase gene and CAD in patients with 
normal kidney function. The rs2576178 polymorphism was 
found to be involved in a CAD risk by Li et al. [14]. Con-
trary to our findings, these authors observed that Chinese 
hypertensive patients with either the AA genotype or the A 
allele were far more likely to develop CAD. The discrep-
ancy between these results and our findings could be attrib-
uted to ethnic differences or different mechanisms for the 
effect of the polymorphism in the presence of chronic kid-
ney disease. The effect could thus depend on the population 
studied. Li et al. did not observe any association between 
rs2296545 polymorphism and CAD risk. Consistent results 
were obtained by Fava et al. [15] of 5696 Swedes from a car-
diovascular cohort of the “Malmö Diet and Cancer” study. 
After a follow-up period of 15 years, researchers did not find 
any association between rs2296545 polymorphism and CAD 
event developed in 408 subjects. In a study of Fava et al., 
rs2576178 polymorphism did not affect the CAD risk.
Farzaneh-Far et al. [16] in the study of 590 Caucasian 
individuals with stable CAD revealed that the CC genotype 
of rs2296545 polymorphism was associated with a left ven-
tricular hypertrophy, systolic and diastolic dysfunction of 
the heart, poor exercise capacity and inducible ischemia.
Table 2  Results of multivariate logistic regression analysis of the 
rs10887800 polymorphism effect on CAD risk under three models of 
genetic inheritance
Genotype distribution is presented as numbers (%). HWE test for 
CAD+ χ2 = .18, p = .669, for CAD− χ2 = 1.80, p = .180
CAD coronary artery disease
a Odds ratios adjusted for age, sex, smoking status, BMI hyperlipi-
demia, arterial hypertension, diabetes mellitus and stroke in anamne-
sis
Rs10887800






ORa (95 % CI) p
Codominant model
 AA 24 (22.4) 53 (26.2) Reference –
 AG 51 (47.7) 110 (54.5) 1.41 (.71–2.80) .322
 GG 32 (29.9) 39 (19.3) 2.66 (1.19–5.94) .017
Dominant model
 AA 24 (22.4) 53 (26.2) Reference –
 AG + GG 83 (77.6) 149 (73.8) 1.72 (.90–3.29) .100
Recessive model
 AG + AA 75 (70.1) 163 (80.7) Reference –
 GG 32 (29.9) 39 (19.3) 2.10 (1.10–4.02) .025
Table 3  Results of multivariate logistic regression analysis of the 
rs2576178 polymorphism effect on CAD risk under three genetic 
models of inheritance
Genotype distribution is presented as numbers (%). HWE test for 
CAD+ χ2 = .11, p = .735, for CAD− χ2 = .02, p = .888
CAD coronary artery disease
a Odds ratios adjusted for age, sex, smoking status, BMI hyperlipi-
demia, arterial hypertension, diabetes mellitus and stroke in anamne-
sis
Rs2576178






ORa (95 % CI) p
Codominant model
 AA 54 (50.5) 114 (56.4) Reference –
 AG 43 (40.2) 75 (37.1) 1.38 (.77–2.46) .269
 GG 10 (9.3) 13 (6.4) 2.10 (.67–6.60) .202
Dominant model
 AA 54 (50.5) 114 (56.4) Reference –
 AG + GG 53 (49.5) 88 (43.5) 1.46 (.84–2.55) .174
Recessive model
 AG + AA 97 (90.7) 189 (93.5) Reference –
 GG 10 (9.3) 13 (6.4) 1.83 (.60–5.58) .286
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The specific pathway by which rs10887800 polymor-
phism modified the risk of CAD remains unknown. The 
analyzed SNP is located near exon/intron boundary in a 
putative functional region, and thus, it might affect gene 
regulation and expression and lead to an altered amount 
of renalase produced. It was demonstrated in animal stud-
ies that deficiency of circulating renalase increased plasma 
catecholamine levels, decreased tolerance to ischemia and 
aggravated ischemic myocardial damage [17]. In another 
paper, renalase administration reduced myocardial damage 
during acute ischemia [18]. Zhou et al. [19] in the study 
of ApoE(–/–) mice suggested that renalase gene could be a 
potential-related gene of lipid metabolism and atheroscle-
rosis. Furthermore, it was suspected that renalase could be 
the possible molecular target of valsartan to help stabilize 
atherosclerotic plaque. Thus, apart from the role of circu-
lating renalase, the role of renalase expressed in a local car-
diac tissue both in cardiomyocytes and in coronary arterial 
endothelium could be taken into consideration in the patho-
genesis of CAD. Other unknown enzymatic functions of 
the renalase should be considered as well.
Human studies provided contradictory results. In the 
study of He et al. [20], plasma renalase level reversely cor-
related with the severity of the CAD in Chinese population, 
whereas Maciorowska et al. [21] observed an increased 
renalase level in the presence of CAD in hypertensive Cau-
casian individuals. Interestingly, Stojanovic et al. [22] have 
recently demonstrated that increased renalase concentration 
was a risk factor for reduced estimated glomerular filtration 
rate (eGFR < 60 ml/min/1.73 m2) in stable renal transplant 
recipients (RTR). Thus, the authors concluded that renalase 
could play a role in the development of late complications, 
including cardiovascular disorder after successful renal 
transplantation. Furthermore, since they observed higher 
renalase level in patients receiving cyclosporine compared 
to those on tacrolimus, they suggested that the activation 
of the sympathetic nervous system, rather than endothelial 
reduction of nitric oxide participated in the pathogenesis of 
cyclosporine-induced hypertension in RTR population.
Some limitations should be considered in the interpre-
tation of our results. The study population involved only 
Caucasian individuals. Therefore, the results may not be 
generalized to other ethnic groups. Furthermore, serum 
renalase level or its activity which could be useful to clarify 
the obtained association was not determined. However, it 
will be the subject of ongoing studies.
Conclusion
The present case–control study suggested for the first 
time that the rs10887800 renalase gene polymorphism 
may influence the susceptibility to CAD in hemodialyzed 
patients. The studied SNP could thus be considered as a 
novel genetic risk factor for CAD in hemodialyzed patients. 
Even though there are a lot of open questions, the presented 
results put an important value in understanding the mech-
anism of cardiovascular complications in patients with 
ESRD. Replication in a larger size sample and other ethnic 
groups are required to confirm the obtained association.
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